Brian R. Thompson

Brian R. Thompson

Auto-generated profile, based on publicly available information

Brian R. Thompson

Global PK/PD and Pharmacometrics Eli Lilly and Company Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
BTBrian R. Thompson
Brian R. Thompson
JSJian Shi
Jian Shi
HZHao-Jie Zhu
Hao-Jie Zhu
DSDavid Smith
David Smith

19 September 2016 in Viruses
Verified
Journal Article
Open access
PDF file
TRTiffiny Rye-McCurdy
Tiffiny Rye-McCurdy
EOErik D. Olson
Erik D. Olson
SLShuohui Liu
Shuohui Liu
CBChristiana Binkley
Christiana Binkley
JRJoshua-Paolo Reyes
Joshua-Paolo Reyes
KMKarin Musier-Forsyth
Karin Musier-Forsyth
Retroviruses specifically package full-length, dimeric genomic RNA (gRNA) even in the presence of a vast excess of cellular RNA. The “psi” (Ψ) element within the 5′-untranslated region (5′UTR) of gRNA is critical for packaging through interaction with the nucleocapsid (NC) domain of Gag. However, in vitro Gag binding affinity for Ψ versus non-Ψ RNAs is not significantly different. Previous salt-titration binding assays revealed that human immunodeficiency virus type 1 (HIV-1) Gag bound to Ψ RNA with high specificity and relatively few charge interactions, whereas binding to non-Ψ RNA was less specific and involved more electrostatic interactions. The NC domain was critical for specific Ψ binding, but surprisingly, a Gag mutant lacking the matrix (MA) domain was less effective at discriminating Ψ from non-Ψ RNA. We now find that Rous sarcoma virus (RSV) Gag also effectively discriminates RSV Ψ from non-Ψ RNA in a MA-dependent manner. Interestingly, Gag chimeras, wherein the HIV-1 and RSV MA domains were swapped, maintained high binding specificity to cognate Ψ RNAs. Using Ψ RNA mutant constructs, determinants responsible for promoting high Gag binding specificity were identified in both systems. Taken together, these studies reveal the functional equivalence of HIV-1 and RSV MA domains in facilitating Ψ RNA selectivity by Gag, as well as Ψ elements that promote this selectivity.

20 March 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
VSVikram M. Shenoy
Vikram M. Shenoy
BTBrian R. Thompson
Brian R. Thompson
JSJian Shi
Jian Shi
HZHao-Jie Zhu
Hao-Jie Zhu
DSDavid E. Smith
David E. Smith
GAGordon L. Amidon
Gordon L. Amidon

6 May 2022 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
JXJingcheng Xiao
Jingcheng Xiao
JSJian Shi
Jian Shi
BTBrian R. Thompson
Brian R. Thompson
DSDavid E. Smith
David E. Smith
TZTao Zhang
Tao Zhang
HZHao-Jie Zhu
Hao-Jie Zhu

1 October 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
BTBrian R. Thompson
Brian R. Thompson
YHYongjun Hu
Yongjun Hu
DSDavid Smith
David Smith

21 August 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
MPMaria M. Posada
Maria M. Posada
KSKaren B. Schneck
Karen B. Schneck
BMBridget L. Morse
Bridget L. Morse
LRLuc R. A. Rougee
Luc R. A. Rougee
LTLai San Tham
Lai San Tham
GDGemma L. Dickinson
Gemma L. Dickinson
Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches. In clinical studies, the gastric emptying delay (GED) was evaluated in healthy participants and patients with T2DM at various dose levels of dulaglutide. A PopPK model estimated the exposure‐dependent delay in gastric emptying, which was then input into the orally administered small molecule PBPK models. These PBPK models, informed by internal clinical studies and publicly available data, quantified the effect of dulaglutide‐induced GED on the area under the curve (AUC), maximum concentration ( C max ), and time to maximum concentration ( t max ) of the co‐administered drugs. The modeling approach was verified for reproducing observed GED‐mediated drug–drug interactions (DDIs) at low doses of dulaglutide and to predict DDIs at a 4.5 mg dulaglutide dose. The clinical studies demonstrated that the 1.5 mg dulaglutide dose has no clinically relevant effect on the pharmacokinetics of small molecules, and the modeling led to a similar conclusion at 4.5 mg dulaglutide. This work demonstrates that modeling approaches can be used to predict potential GLP‐1‐mediated DDIs related to gastric emptying delay, increasing the efficiency of the clinical pharmacology programs.